Biocryst Pharmaceuticals (BCRX) Income towards Parent Company: 2010-2015
Historic Income towards Parent Company for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to -$14.3 million.
- Biocryst Pharmaceuticals' Income towards Parent Company fell 11.36% to -$14.3 million in Q3 2015 from the same period last year, while for Sep 2015 it was -$42.2 million, marking a year-over-year decrease of 0.88%. This contributed to the annual value of -$50.7 million for FY2014, which is 43.14% down from last year.
- Latest data reveals that Biocryst Pharmaceuticals reported Income towards Parent Company of -$14.3 million as of Q3 2015, which was down 443.67% from $4.2 million recorded in Q2 2015.
- Biocryst Pharmaceuticals' Income towards Parent Company's 5-year high stood at $4.2 million during Q2 2015, with a 5-year trough of -$16.4 million in Q4 2014.
- Over the past 3 years, Biocryst Pharmaceuticals' median Income towards Parent Company value was -$12.8 million (recorded in 2014), while the average stood at -$10.2 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 117.43% in 2014, then spiked by 132.37% in 2015.
- Over the past 5 years, Biocryst Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$12.1 million in 2011, then climbed by 3.47% to -$11.3 million in 2012, then decreased by 17.79% to -$7.6 million in 2013, then plummeted by 117.43% to -$16.4 million in 2014, then fell by 11.36% to -$14.3 million in 2015.
- Its Income towards Parent Company was -$14.3 million in Q3 2015, compared to $4.2 million in Q2 2015 and -$15.6 million in Q1 2015.